Search

Your search keyword '"Jacoby, Meagan A."' showing total 42 results

Search Constraints

Start Over You searched for: Author "Jacoby, Meagan A." Remove constraint Author: "Jacoby, Meagan A." Database ScienceDirect Remove constraint Database: ScienceDirect
42 results on '"Jacoby, Meagan A."'

Search Results

10. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

11. Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen

13. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

15. Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” [Leukemia Res. 104 March (2021)]

16. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

17. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

18. 386 - A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

19. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy

27. Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes

30. Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients

31. Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

32. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Catalog

Books, media, physical & digital resources